Joint association of sedentary behaviour and physical activity with cardiovascular disease: a systematic review and meta-analysis.

Eur J Prev CardiolSep 8, 2026
Clinical ResearchCardiology

Frances Rom Lunar, Zhen Du, Shiho Amagasa et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the joint association of physical activity (PA) and sedentary behaviour (SB) with cardiovascular disease (CVD) risk in adults. Analyzing data from 17 studies, the lowest PA combined with the highest SB was linked to a 1.78-fold increased risk for CVD compared to the highest PA and lowest SB group.

Key findings

  • Lowest PA + highest SB group had a CVD risk of 1.78 (95% CI: 1.59-2.00) compared to the highest PA + lowest SB group.
  • Lowest PA + lowest SB group showed a CVD risk of 1.25 (95% CI: 1.12-1.40) compared to the reference group.
  • Highest PA + highest SB group had a CVD risk of 1.16 (95% CI: 1.06-1.27) compared to the reference group.

Why it matters

Understanding the combined effects of physical activity and sedentary behaviour on cardiovascular disease risk is crucial for developing effective prevention strategies. This research underscores the importance of addressing both behaviours in clinical assessments and interventions.

Source

PubMed · PMID 42116645

Published in Eur J Prev Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.